Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 10846
Sealed predictions
- SLC2A3 in dopamine neurons, braak+0.33 (p 0.380) → +0.42 (p 0.258)receipt 10855
Swarm cases
receipt 10855: SLC2A3 in dopamine neurons, braak
- power
- full sample +0.41 (p 0.091, n 18), 95% CI -0.07 to +0.74. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.101, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.057, n 18). could be the mix.
- skeptic
- leave-one-out range +0.32 to +0.56, sign flips 0; without severely affected donors +0.41 (p 0.091, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC2A3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts